Despite over 300 clinical trials having been performed targeting either of the proposed toxic mediators in AD, Aβ and hyperphosphorylated tau, we do not as yet have any successful therapeutic approaches for the disease. This evidence concerns the gene MAPT and Alzheimer disease.